



Canadian CLL Treatment Options

Relapsed/refractory
CLL/SLL requiring treatment

Without del(17p)
or TP53 mutation

With del(17p) or
TP53 mutation

Previous BTKi
treatment

No previous BTKi
treatment

Previous BTKi
treatment

No previous
BTKi treatment

**venetoclax
+/- rituximab
or
idelalisib
+ rituximab**

**venetoclax +/- rituximab;
ibrutinib;
idelalisib + rituximab;
or retreatment with
chemoimmunotherapy***
(may be an option in selected low risk patients
with a prolonged response to first line
chemotherapy)

**venetoclax +/-
rituximab
or
idelalisib
+ rituximab**

**venetoclax +/-
rituximab;
ibrutinib;
or idelalisib +
rituximab**

